From: Suppressor of cytokine signaling (SOCS) genes are downregulated in breast cancer
SOCS1 upregulation | SOCS1 downregulation | P value | SOCS2 upregulation | SOCS2 downregulation | P value | SOCS3 upregulation | SOCS3 downregulation | P value | SOCS5 upregulation | SOCS5 downregulation | P value | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age | 0.35 | 0.5 | 0.84 | 0.68 | ||||||||
< 55 years | 11 (32.4%) | 23 (67.6%) | 9 (26.5%) | 25 (73.5%) | 11 (32.4%) | 23 (67.6%) | 10 (29.4%) | 24 (70.6%) | ||||
≥ 55 years | 9 (45%) | 11 (55%) | 7 (35%) | 13 (65%) | 7 (35%) | 13 (65%) | 5 (25%) | 15 (75%) | ||||
Stage | 0.95 | 0.81 | 0.8 | 0.86 | ||||||||
1 | 5 (31.3%) | 11 (68.7%) | 5 (31.3%) | 11 (68.7%) | 4 (25%) | 12 (75%) | 3 (18.8%) | 13 (81.2%) | ||||
2 | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 5 (33.3%) | 10 (66.7%) | ||||
3 | 7 (43.8%) | 9 (56.3%) | 4 (25%) | 12 (75%) | 5 (31.2%) | 11 (68.8%) | 5 (31.2%) | 11 (68.8%) | ||||
4 | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | 2 (40%) | 3 (60%) | 1 (20%) | 4 (80%) | ||||
Histological grade | 0.32 | 0.18 | 0.08 | 0.19 | ||||||||
1 | 2 (25%) | 6 (75%) | 1 (12.5%) | 7 (87.5%) | 0 (0%) | 8 (100%) | 0 (0%) | 8 (100%) | ||||
2 | 12 (52.2%) | 11 (47.8%) | 10 (43.5%) | 13 (56.5%) | 9 (39.1%) | 14 (60.9%) | 8 (34.8%) | 15 (65.2%) | ||||
3 | 5 (31.3%) | 11 (68.8%) | 3 (18.8%) | 13 (81.2%) | 7 (43.8%) | 9 (56.2%) | 4 (25%) | 12 (75%) | ||||
Mitotic rate | 0.36 | 0.03 | 0.9 | 0.16 | ||||||||
1 | 10 (52.6%) | 9 (47.4%) | 10 (52.6%) | 9 (47.4%) | 8 (42.1%) | 11 (57.9%) | 8 (42.1%) | 11 (57.9%) | ||||
2 | 6 (33.3%) | 12 (66.7%) | 4 (22.2%) | 14 (77.8%) | 6 (33.3%) | 12 (66.7%) | 4 (22.2%) | 14 (77.8%) | ||||
3 | 1 (20%) | 4 (80%) | 0 (0%) | 5 (100%) | 2 (40%) | 3 (60%) | 0 (0%) | 5 (100%) | ||||
Tumor size | 0.26 | 0.29 | 1 | 0.38 | ||||||||
< 2 | 4 (25%) | 12 (75%) | 5 (31.3%) | 11 (68.8%) | 5 (31.3%) | 11 (68.8%) | 4 (25%) | 12 (75%) | ||||
2–5 | 15 (45.5%) | 18 (54.5%) | 9 (27.3%) | 24 (72.7%) | 11 (33.3%) | 12 (66.7%) | 8 (24.2%) | 25 (75.8%) | ||||
> 5 | 0 (0%) | 1 (100%) | 1 (100%) | 0 (0%) | 0 (0%) | 1 (100%) | 1 (100%) | 0 (0%) | ||||
ER state | 0.81 | 0.63 | 1 | 0.36 | ||||||||
Positive | 16 (38.1%) | 26 (61.9%) | 13 (31%) | 29 (69%) | 14 (33.3%) | 28 (66.7%) | 10 (23.8%) | 32 (76.2%) | ||||
Negative | 3 (42.9%) | 4 (57.1%) | 2 (28.6%) | 5 (71.4%) | 2 (28.6%) | 5 (71.4%) | 3 (42.9%) | 4 (57.1%) | ||||
PR state | 0.8 | 0.72 | 0.33 | 0.45 | ||||||||
Positive | 15 (40.5%) | 22 (59.5%) | 11 (29.7%) | 26 (70.3%) | 11 (29.7%) | 26 (70.3%) | 9 (24.3%) | 28 (75%) | ||||
Negative | 4 (36.4%) | 7 (63.6%) | 4 (36.4%) | 7 (63.6%) | 5 (45.5%) | 6 (54.5%) | 4 (36.4%) | 7 (63.6%) | ||||
Her2 state | 0.39 | 0.85 | 0.15 | 0.18 | ||||||||
Positive | 6 (50%) | 6 (50%) | 4 (33.3%) | 8 (66.7%) | 6 (50%) | 6 (50%) | 5 (41.7%) | 7 (58.3%) | ||||
Negative | 13 (36.1%) | 23 (63.9%) | 11 (30.6%) | 25 (69.4%) | 10 (27.8%) | 26 (72.2%) | 8 (22.2%) | 28 (77.8%) | ||||
Breast feeding duration (months) | 0.3 | 0.84 | 0.08 | 0.19 | ||||||||
0 | 4 (50%) | 4 (50%) | 2 (25%) | 6 (75%) | 5 (62.5%) | 3 (37.5%) | 4 (50%) | 4 (50%) | ||||
1–30 | 8 (53.3%) | 7 (46.7%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | 6 (40%) | 9 (60%) | ||||
31–60 | 5 (27.8%) | 13 (72.2%) | 5 (27.8%) | 13 (72.2%) | 6 (33.3%) | 12 (66.7%) | 3 (16.7%) | 15 (83.3%) | ||||
61–120 | 3 (25%) | 9 (75%) | 3 (25%) | 9 (75%) | 1 (8.3%) | 11 (91.7%) | 2 (16.7%) | 10 (83.3%) |